Drug intelligence / Profile preview

bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen)

Development stage: Unknown
Lead developer: Grupo Cooperativo GEMCAD
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen) refers to the stratified monoclonal antibody therapy used in the LIVERPEARL-I clinical trial (NCT03088332) sponsored by the Grupo Español Multidisciplinario del Cancer Digestivo (GEMCAD). This treatment strategy involves the administration of either bevacizumab (an anti-VEGF antibody) or an anti-EGFR antibody (such as cetuximab or panitumumab) in combination with modified FOLFOX6 (FOLFOX6m) chemotherapy. The choice of antibody is determined by the patient's RAS mutational status: RAS-mutated patients receive bevacizumab, while RAS wild-type patients receive an anti-EGFR agent. This regimen is used as the systemic backbone to treat patients with colorectal cancer and liver-limited metastases, often compared against the addition of irinotecan-loaded microsphere chemoembolization.

Other names: FOLFOX6m + mAb (GEMCAD)bevacizumab or anti-EGFR with FOLFOX6m

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + anti-EGFR (GEMCAD LIVERPEARL regimen).

Explore the full profile